This is a case report of successfully treating hemorrhage with rFVIIa in four patients with factor VIII and one with factor V inhibitor. One patient was initially treated with APCC (Autoplex) and blood products unsuccessfully. The authors confirm the efficacy and safety of rFVIIa and suggest carrying out cost effectiveness analysis. Further information is required […]
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
This study reports the effective use of rFVIIa in covering 20 surgical procedures in 12 patients with hemophilia VIII with high inhibitors, in addition to treating 6 episodes of severe bleeding in 3 patients successfully. All but one of the surgical procedures were insertion or removal of a central venous access device. This paper again […]
Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
This is another case report of a successful use of rFVIIa in covering knee replacement surgery in a patient with severe hemophilia A and high-titer inhibitor. rFVIIa was given at a dose of 85 u/kg at 2-hourly interval initially, increasing the interval between infusions every 48 hours. Effective hemostasis was achieved. The authors recommend administering […]
Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A.
This is a very interesting article which casts new light on the mechanism of hemostasis of rFVIIa in hemophiliac patients with inhibitors to factor VIII. rFVIIa is known to exert its hemostatic effect by binding with tissue factor and activation of factors IX, X and XI, and formation of thrombin burst. This study shows that […]
This is another excellent review of the mechanism of action, indications, and various doses of rFVIIa (Novoseven) in hereditary bleeding disorders. Its main use has been in patients with factor VIII or IX deficiency with inhibitors, where rFVIIa can by-pass factors VIII or IX, interacts with tissue factor and generates thrombin in addition to activating […]
Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.
A good overall review on the characterization, mechanism of action, and preclinical and current clinical evidence for the efficacy and safety of rFVIIa. – M. Aldouri.